A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy
CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

BIOLOGICAL: Empasiprubart IV
OTHER: Placebo IV

Sponsor

argenx